[1]黄 剑,葛乃建,徐 伟,等.TACE联合卡瑞利珠单抗及甲磺酸阿帕替尼治疗晚期肝细胞癌16例[J].介入放射学杂志,2021,30(08):774-779.
 HUANG Jian,GE Naijian,XU Wei,et al.TACE combined with camrelizumab and apatinib for advanced hepatocellular carcinoma: preliminary results in 16 patients[J].journal interventional radiology,2021,30(08):774-779.
点击复制

TACE联合卡瑞利珠单抗及甲磺酸阿帕替尼治疗晚期肝细胞癌16例()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
30
期数:
2021年08
页码:
774-779
栏目:
肿瘤介入
出版日期:
2021-08-25

文章信息/Info

Title:
TACE combined with camrelizumab and apatinib for advanced hepatocellular carcinoma: preliminary results in 16 patients
作者:
黄 剑 葛乃建 徐 伟 于晓河 石志勇 蔡 飞 张小锋 周小琴 杨业发
Author(s):
HUANG Jian GE Naijian XU Wei YU Xiaohe SHI Zhiyong CAI Fei ZHANG Xiaofeng ZHOU Xiaoqin YANG Yefa.
Minimally-Invasive Intervention Center, Affiliated Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai 200438, China
关键词:
【关键词】 肝细胞癌 经导管肝动脉化疗栓塞术 卡瑞利珠单抗 甲磺酸阿帕替尼
文献标志码:
A
摘要:
【摘要】 目的 评估TACE联合卡瑞利珠单抗及甲磺酸阿帕替尼治疗晚期肝细胞癌(HCC)的安全性及疗效。方法 回顾性分析我科2019年1月至2020年12月接受TACE联合卡瑞利珠单抗及阿帕替尼治疗的HCC患者临床资料。依据NCI- CTCAE(National Cancer Institute’s Common Terminology Criteria for Adverse Events)标准评估患者联合治疗后不良事件发生率,依据mRECIST标准分析患者肿瘤完全缓解(CR)率、部分缓解(PR)率、稳定(SD)、肿瘤进展(PD)、疾病控制率(DCR)、无进展生存期(PFS)及总生存期(OS)。采用SPSS软件对患者随访数据进行分析。结果 收集联合治疗资料完善且符合本研究方案的患者16例。中位随访时间11个月(3~26个月)。TACE术后16(100%)例患者均出现栓塞后综合征,14(87.5%,95%CI,69.3%~100%)例患者出现靶向药及PD- 1相关并发症,其中6例(37.5%)患者出现3级并发症,包括2例(12.5%,95%CI,0~30.7%)手足综合征、3例(18.75%,95%CI,0- 40.2%)腹泻及1例(6.2%,95%CI,0~19.6%)免疫性肺炎。16例患者中2例(12.5%,95%CI,0~30.7%)CR,10例(62.5%,95%CI,35.9%~89.1%)PR,2例(12.5%,95%CI,0~30.7%)SD; 14例(87.5%,95%CI,69.3%~100%)DCR。中位PFS长达9个月(95%CI, 5.58~13.29个月),中位OS长达 12个月(95%CI,9.04~16.09个月)。结论 TACE联合卡瑞利珠单抗及甲磺酸阿帕替尼治疗晚期肝细胞癌严重不良事件发生率低、肿瘤控制率高,患者生存明显获益。

参考文献/References:

[1] European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2018, 69: 182- 236.
[2] Kudo M. Systemic therapy for hepatocellular carcinoma: 2017 update[J]. Oncology, 2017, 93(Suppl 1): 135- 146.
[3] 中国介入医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗(TACE)临床实践指南[J]. 介入放射学杂志, 2018, 27:1117- 1126.
[4] Kudo M, Matsui O, Izumi N,et al. Transarterial chemoembo-lization failure/refractoriness: JSH- LCSGJ criteria 2014 update[J]. Oncology, 2014, 87(Suppl 1): 22- 31.
[5] Jindal A, Thadi A, Shailubhai K. Hepatocellular carcinoma: etiology and current and future drugs[J]. J Clin Exp Hepatol, 2019, 9: 221- 232.
[6] Doycheva I, Thuluvath PJ. Systemic therapy for advanced hepatocellular carcinoma: an update of a rapidly evolving field[J]. J Clin Exp Hepatol, 2019, 9: 588- 596.
[7] Xu J, Zhang Y, Jia R, et al. Anti- PD- 1 antibody SHR- 1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open- label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25: 515- 523.
[8] Basch E, Reeve BB, Mitchell SA,et al. Development of the National Cancer Institute’s patient- reported outcomes version of the common terminology criteria for adverse events(PRO- CTCAE)[J]. J Natl Cancer Inst, 2014, 106 :dju244.
[9] Lencioni R, Llovet JR. Assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30: 52- 60.
[10] Kudo M, Ueshima K, Kubo S,et al. Response Evaluation Criteria in Cancer of the Liver(RECICL)(2015 revised version)[J]. Hepatol Res, 2016, 46: 3- 9.
[11] Marrero JA, Kulik LM, Sirlin CB, et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases[J]. Hepatology, 2018, 68: 723- 750.
[12] Kong Y, Sun L, Hou Z, et al. Apatinib is effective for treatment of advanced hepatocellular carcinoma[J]. Oncotarget, 2017, 8: 105596- 105605.
[13] Waidmann O. Recent developments with immunotherapy for hepa- tocellular carcinoma[J]. Expert Opin Biol Ther, 2018, 18: 905- 910.
[14] Zhu AX, Finn RS, Edeline J,et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib(KEYNOTE- 224): a non- randomised, open- label phase 2 trial[J]. Lancet Oncol, 2018,19: 940- 952.
[15] Schoenfeld AJ, Arbour KC, Rizvi H, et al. Severe immune- related adverse events are common with sequential PD- (L)1 blockade and osimertinib[J]. Ann Oncol, 2019, 30: 839- 844.
[16] Park JW, Koh YH, Kim HB, et al. Phase Ⅱ study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma[J]. J Hepatol, 2012, 56: 1336- 1342.
[17] 陈 成,沈艳峰,董 云,等. 阿帕替尼联合TACE治疗原发性肝癌有效性和安全性meta分析[J]. 介入放射学杂志, 2020, 29:251- 259.

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良RECIST标准更可靠[J].介入放射学杂志,2012,(03):177.
 . Therapeutic evaluation criterion of inoperable hepatocellular carcinomas: modified RECIST as a more reliable standard[J].journal interventional radiology,2012,(08):177.
[2]吴纪瑞,杨永岩,杨熙章,等.丝裂霉素C微囊肝动脉化疗栓塞术治疗中晚期肝癌[J].介入放射学杂志,1992,(01):41.
[3]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
 .The transformation pattern of serum аfetoprotein after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma: its clinical significance [J].journal interventional radiology,2012,(08):333.
[4]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
 ,,et al.The factors related to the formation of arterioportal shunting in patients with hepatocellular carcinomas [J].journal interventional radiology,2012,(08):206.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ;[J].介入放射学杂志,2012,(06):469.
 SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(08):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
 LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(08):974.
[7]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
 PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(08):636.
[8]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
 LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms: recent advances in research[J].journal interventional radiology,2013,(08):520.
[9]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
 YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma: analysis of treatment interval[J].journal interventional radiology,2014,(08):769.
[10]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
 YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma: a clinical analysis of 50 cases[J].journal interventional radiology,2013,(08):381.

备注/Memo

备注/Memo:
(收稿日期:2021- 04- 10)
(本文编辑:俞瑞纲)
更新日期/Last Update: 2021-08-18